Long-term safety of drospirenone-estradiol for hormone therapy: A randomized, double-blind, multicenter trial

Menopause

Volumn 12, Issue 6, 2005, Pages 716-727

  Archer, David F ^a   Thorneycroft, Ian H ^b   Foegh, Marie ^c   Hanes, Vladimir ^c   Glant, Michael D ^d   Bitterman, Pincas ^e   Kempson, Richard L ^f  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

^c BAYER PHARMA AG   (Germany)

^d DCL Medical Laboratories   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aldosterone antagonists; Drospirenone; Endometrial bleeding; Endometrium; Hormone therapy; Lipids; Postmenopausal women

Indexed keywords

DROSPIRENONE PLUS ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOMETRIUM HYPERPLASIA; FEMALE; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; MULTICENTER STUDY; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ALDOSTERONE ANTAGONISTS; ANDROSTENES; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FEMALE UROGENITAL DISEASES; HOT FLASHES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SATISFACTION; POSTMENOPAUSE; QUALITY OF LIFE; TREATMENT OUTCOME; UTERINE HEMORRHAGE;

EID: 27944452237     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000177318.24005.b1     Document Type: Article

References (21)

1. Witt DM, Lousberg TR. Controversies surrounding estrogen use in postmenopausal women. Ann Pharmacother 1997;31:745-755.
2. Ettinger B, Golditch IM, Friedman G. Gynecologic consequences of long-term, unopposed estrogen replacement therapy. Maturitas 1988;10:271-282.
3. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.
4. Corson SL, Richart RM, Caubel P, Lim P. Effect of a unique constant-estrogen, pulsed-progestin hormone replacement therapy containing 17beta-estradiol and norgestimate on endometrial histology. Int J Fertil Womens Med 1999;44:279-285.
5. Cust MP, Gangar KF, Hillard TC, Whitehead MI. A risk-benefit assessment of estrogen therapy in postmenopausal women. Drug Saf 1990;5:345-358.
6. Losert W, Casal-Stenzel J, Buse M. Progestogens with antimineralocorticoid activity. Arzneimittelforschung 1985;35:459-471.
7. Oelkers WKH. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996;61:166-171.
8. Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth VB. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation 2001;104:2826-2831.
9. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-1059.
10. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Estrogen-progestin replacement and risk of breast cancer. JAMA 2000;284:691-694.
11. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-650.
12. Grady D, Herrington D, Bittner V, et al., for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
13. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
14. Oelkers W. Drospirenone - a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care 2000;5(suppl 3):17-24.
15. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002;9:6-15.
16. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38.
17. Skouby SO. The rationale for a wider range of progestogens. Climacteric 2000;3(suppl 2):14-20.
18. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 1995;761:311-335.
19. Oelkers W, Berger V, Bolik A, et al. Dihydrospirenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 1991;73:837-842.
20. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-1821.
21. Korhonen MO, Symons JP, Hyde BM, Rowan JP, Wilborn WH. Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol 1997;176:377-380.